Linee guida AIAC 2010 per la gestione e il trattamento della - Stopfa

The long- and short-term impact of elevated
body mass index on the risk of new atrial
fibrillation: the WHS (women’s health study).
J Am Coll Cardiol 2010;55:2319-27.
50. Aviles RJ, Martin DO, Apperson-
Hansen C, et al. Inflammation as a risk factor
for atrial fibrillation. Circulation
2003;108:3006-10.
51. Wang TJ, Larson MG, Levy D, et al.
Plasma natriuretic peptide levels and the
risk of cardiovascular events and death. N
Engl J Med 2004;350:655-63.
52. Mitchell GF, Vasan RS, Keyes MJ, et al.
Pulse pressure and risk of new-onset atrial
fibrillation. JAMA 2007;297:709-15.
53. Thomas MC, Dublin S, Kaplan RC, et
al. Blood pressure control and risk of incident
atrial fibrillation. Am J Hypertens 2008;
21:1111-6.
54. Rosengren A, Hauptman PJ, Lappas
G, Olsson L, Wilhelmnsen L, Swedberg K.
Big men and atrial fibrillation: effects of
body size and weight gain on risk of atrial
fibrillation in men. Eur Heart J 2009;30:
1113-20.
55. Hanna IR, Heeke B, Bush H, et al. The
relationship between stature and the prevalence
of atrial fibrillation in patients with
left ventricular dysfunction. J Am Coll Cardiol
2006;47:1683-8.
56. Kanagala R, Murali NS, Friedman PA,
et al. Obstructive sleep apnea and the recurrence
of atrial fibrillation. Circulation
2003;107:2589-94.
57. Gami AS, Pressman G, Caples SM, et
al. Association of atrial fibrillation and obstructive
sleep apnea. Circulation 2004;110:
364-7.
58. Gami AS, Hodge DO, Herges RM, et
al. Obstructive sleep apnea, obesity, and the
risk of incident atrial fibrillation. J Am Coll
Cardiol 2007;49:565-71.
59. Watanabe H, Tanabe N, Watanabe T,
et al. Metabolic syndrome and risk of development
of atrial fibrillation: the Niigata
preventive medicine study. Circulation
2008;117:1255-60.
60. Mont L, Elosua R, Brugada J. Endurance
sport practice as a risk factor for
atrial fibrillation and atrial flutter. Europace
2009;11:11-7.
61. Chen J, Wasmund SL, Hamdan MH.
Back to the future: the role of the autonomic
nervous system in atrial fibrillation.
Pacing Clin Electrophysiol 2006;29:413-21.
62. Coumel P. Autonomic influences in
atrial tachyarrhythmias. J Cardiovasc Electrophysiol
1996;7:999-1007.
63. Oral H, Chugh A, Scharf C, et al. Pulmonary
vein isolation for vagotonic, adrenergic,
and random episodes of paroxysmal
atrial fibrillation. J Cardiovasc Electrophysiol
2004;15:402-6.
64. de Vos CB, Nieuwlaat R, Crijns HJ, et
al. Autonomic trigger patterns and anti-arrhythmic
treatment of paroxysmal atrial fibrillation:
data from the Euro Heart Survey.
Eur Heart J 2008;29:632-9.
LINEE GUIDA AIAC 2010 PER LA GESTIONE EIL TRATTAMENTO DELLA FA
65. Kozlowski D, Budrejko S, Lip GY, et al.
Lone atrial fibrillation: what do we know?
Heart 2010;96:498-503.
66. Patton KK, Zacks ES, Chang JY, et al.
Clinical subtypes of lone atrial fibrillation.
Pacing Clin Electrophysiol 2005;28:630-8.
67. Jahangir A, Lee V, Friedman PA, et al.
Long-term progression and outcomes with
aging in patients with lone atrial fibrillation:
a 30-year follow-up study. Circulation
2007;115: 3050-6.
68. Kopecky SL, Gersh BJ, McGoon MD, et
al. The natural history of lone atrial fibrillation.
A population-based study over three
decades. N Engl J Med 1987;317:669-74.
69. Davidson E, Rotenberg Z, Weinberger
I, Fuchs J, Agmon J. Diagnosis and characteristics
of lone atrial fibrillation. Chest
1989;95:1048-50.
70. Osranek M, Bursi F, Bailey KR, et al.
Left atrial volume predicts cardiovascular
events in patients originally diagnosed with
lone atrial fibrillation: three-decade followup.
Eur Heart J 2005;26:2556-61.
71. Scardi S, Mazzone C, Pandullo C,
Goldstein D, Poletti A, Humar F. Lone atrial
fibrillation: prognostic differences between
paroxysmal and chronic forms after 10 years
of follow-up. Am Heart J 1999;137(4 Pt 1):
686-91.
72. Brand FN, Abbott RD, Kannel WB,
Wolf PA. Characteristics and prognosis of
lone atrial fibrillation. 30-year follow-up in
the Framingham Study. JAMA 1985;254:
3449-53.
73. Jouven X, Desnos M, Guerot C,
Ducimetiere P. Idiopathic atrial fibrillation as
a risk factor for mortality. The Paris Prospective
Study I. Eur Heart J 1999;20:896-9.
74. Nanthakumar K, Lau YR, Plumb VJ,
Epstein AE, Kay GN. Electrophysiologic findings
in adolescents with atrial fibrillation
who have structurally normal hearts. Circulation
2004;110:117-23.
75. Kato K, Oguri M, Hibino T, et al. Genetic
factors for lone atrial fibrillation. Int J
Mol Med 2007;19:933-9.
76. Roberts JD, Gollob MH. Impact of genetic
discoveries on the classification of lone
atrial fibrillation. J Am Coll Cardiol 2010;55:
705-12.
77. Kerr C, Boone J, Connolly S, et al. Follow-up
of atrial fibrillation: the initial experience
of the Canadian Registry of Atrial Fibrillation.
Eur Heart J 1996;17(Suppl C):48-51.
78. Kirchhof P, Auricchio A, Bax J, et al.
Outcome parameters for trials in atrial fibrillation:
recommendations from a consensus
conference organized by the German
Atrial Fibrillation Competence NETwork and
the European Heart Rhythm Association.
Europace 2007;9:1006-23.
79. Page RL, Tilsch TW, Connolly SJ, et al.;
Azimilide Supraventricular Arrhythmia Program
(ASAP) Investigators. Asymptomatic
or “silent” atrial fibrillation: frequency in
untreated patients and patients receiving
azimilide. Circulation 2003;107:1141-5.
80. Fetsch T, Bauer P, Engberding R, et al.;
Prevention of Atrial Fibrillation after Cardioversion
Investigators. Prevention of atrial
fibrillation after cardioversion: results of the
PAFAC trial. Eur Heart J 2004;25:1385-94.
81. Patten M, Maas R, Bauer P, et al.;
SOPAT Investigators. Suppression of paroxys -
mal atrial tachyarrhythmias - results of the
SOPAT trial. Eur Heart J 2004;25:1395-404.
82. Israel CW, Gronefeld G, Ehrlich JR, Li
YG, Hohnloser SH. Long-term risk of recurrent
atrial fibrillation as documented by an
implantable monitoring device: implications
for optimal patient care. J Am Coll Cardiol
2004;43:47-52.
83. Glotzer TV, Hellkamp AS, Zimmerman
J, et al.; MOST Investigators. Atrial high rate
episodes detected by pacemaker diagnostics
predict death and stroke: report of the Atrial
Diagnostics Ancillary Study of the MOde
Selection Trial (MOST). Circulation 2003;
107:1614-9.
84. Capucci A, Santini M, Padeletti L, et
al.; Italian AT500 Registry Investigators.
Monitored atrial fibrillation duration predicts
arterial embolic events in patients suffering
from bradycardia and atrial fibrillation
implanted with antitachycardia pacemakers.
J Am Coll Cardiol 2005;46:1913-20.
85. Oral H, Veerareddy S, Good E, et al.
Prevalence of asymptomatic recurrences of
atrial fibrillation after successful radiofrequency
catheter ablation. J Cardiovasc Electrophysiol
2004;15:920-4.
86. Hindricks G, Piorkowski C, Tanner H,
et al. Perception of atrial fibrillation before
and after radiofrequency catheter ablation:
relevance of asymptomatic arrhythmia recurrence.
Circulation 2005;112:307-13.
87. Senatore, G, Stabile G, Bertaglia E, et
al. Role of transtelephonic electrocardiographic
monitoring in detecting short-term
arrhythmia recurrences after radiofrequency
ablation in patients with atrial fibrillation. J
Am Coll Cardiol 2005;45:873-6.
88. Neumann T, Erdogan A, Dill T, et al.
Asymptomatic recurrences of atrial fibrillation
after pulmonary vein isolation. Euro -
pace 2006;8:495-8.
89. Vasamreddy C, Dalal D, Dong J, et al.
Symptomatic and asymptomatic atrial fibrillation
in patients undergoing radiofrequency
catheter ablation. J Cardiovasc Electro -
physiol 2006;17:134-9.
90. Klemm HU, Ventura R, Rostock T, et al.
Correlation of symptoms to ECG diagnosis
following atrial fibrillation ablation. J Cardiovasc
Electrophysiol 2006;17:146-50.
91. Verma A, Minor S, Kilicaslan F, et al. Incidence
of atrial arrhythmias detected by
permanent pacemakers (PPM) post-pulmonary
vein antrum isolation (PVAI) for
atrial fibrillation (AF): correlation with symptomatic
recurrence. J Cardiovasc Electrophysiol
2007;18:601-6.
92. Steven D, Rostock T, Lutomsky B, et al.
What is the real atrial fibrillation burden after
catheter ablation of atrial fibrillation? A
G ITAL CARDIOL | VOL 12 | SUPPL 1 AL N 1 2011
51